Journal
Journal of Cheminformatics
Journal of Cheminformatics is an open access journal publishing original peer-reviewed research in all aspects of cheminformatics and molecular modelling.
In light of the 15th anniversary of the Journal of Cheminformatics, we introduce this special collection of Commentaries entitled Milestones in Cheminformatics.
Pioneers and experts will discuss what, in their views, are the greatest of all time concepts, methodologies, and developments that have pushed the boundaries of cheminformatics to its current form, as well as forthcoming challenges and opportunities. Broad topics include:
• an overall account of the cheminformatics field;
• theoretical aspects and applications of chemical spaces;
• education;
• publishing;
• predictive models of bioactivity;
• job market/career development;
• compound databases;
• data analysis and visualization;
• open science/open data;
• and software / web-servers.
Submit your manuscript to this collection through the participating journal.
-
Karina Martinez-Mayorga
Dr. Martinez-Mayorga is an expert in the field Computational Biological Chemistry. She has PhD degree in Chemical Sciences from UNAM, Mexico. In 2005, Dr. Martinez joined Professor Michael F. Brown’s group at the University of Arizona as a postdoc, performing computational and experimental research on membrane proteins and lipid. Her current lines of research focus on molecular recognition studies, the identification of bioactive molecules in databases and the prediction of toxicity, all using computational methods. -
José L. Medina-Franco
Dr. José Medina-Franco is a full professor at School of Chemistry, UNAM Mexico. He has more than 8 years of experience working on molecular modeling of DNMT inhibitors. He has led one of the first research groups applying computational tools for drug discovery of epi-hits. His research group has published several research papers, reviews and book chapters focused on the development of DNMT inhibitors using computational methods. One of the major contributions of his group has been the identification of a distinct DNMT inhibitor with a novel molecular scaffold.